ArticleArchives of microbiology2026
Antimicrobial and antibiofilm activity of selected flavonoids against pathogenic Leptospira species.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptospirosis is a widespread zoonotic disease where biofilm formation significantly hinders treatment, contributing to chronic infections. This preliminary study evaluated the antimicrobial and antibiofilm properties of four flavonoids-apigenin, xanthohumol, quercetin, and luteolin-against Leptospira santarosai (sv. Guaricura), L. interrogans (sv. Copenhageni and Hardjoprajitno), and L. borgpetersenii (sv. Hardjobovis). Using microdilution methods, quercetin and apigenin exhibited superior antimicrobial activity, reaching MICs of ≤ 0.12 µg/mL for L. santarosai sv. Guaricura. In antibiofilm assays, quercetin was the most effective compound, successfully disrupting biofilm at minimal biofilm disruptive concentrations (MBDC) as low as < 0.0012 µg/µL for L. santarosai sv. Guaricura and for L. interrogans sv. Copenhageni and Hardjoprajitno. These findings highlight the potential therapeutic candidates, requiring further evaluation, for managing both acute and persistent forms of leptospirosis, either alone or as adjuvants to current antibiotic therapies. Further in vivo studies are warranted to confirm their therapeutic safety and clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.